ANVS vs. CRMD, NATR, MRSN, ADCT, RANI, ANL, ENTA, ME, ATAI, and AQST
Should you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include CorMedix (CRMD), Nature's Sunshine Products (NATR), Mersana Therapeutics (MRSN), ADC Therapeutics (ADCT), Rani Therapeutics (RANI), Adlai Nortye (ANL), Enanta Pharmaceuticals (ENTA), 23andMe (ME), Atai Life Sciences (ATAI), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical preparations" industry.
Annovis Bio (NYSE:ANVS) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.
Annovis Bio received 5 more outperform votes than CorMedix when rated by MarketBeat users. Likewise, 95.24% of users gave Annovis Bio an outperform vote while only 71.43% of users gave CorMedix an outperform vote.
15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 38.3% of Annovis Bio shares are held by company insiders. Comparatively, 3.6% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Annovis Bio had 3 more articles in the media than CorMedix. MarketBeat recorded 4 mentions for Annovis Bio and 1 mentions for CorMedix. Annovis Bio's average media sentiment score of 0.88 beat CorMedix's score of 0.00 indicating that Annovis Bio is being referred to more favorably in the media.
Annovis Bio currently has a consensus price target of $32.20, indicating a potential upside of 421.88%. CorMedix has a consensus price target of $13.00, indicating a potential upside of 151.94%. Given Annovis Bio's higher probable upside, research analysts clearly believe Annovis Bio is more favorable than CorMedix.
CorMedix has higher revenue and earnings than Annovis Bio. CorMedix is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.
Annovis Bio has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500.
CorMedix's return on equity of -77.17% beat Annovis Bio's return on equity.
Summary
Annovis Bio beats CorMedix on 8 of the 15 factors compared between the two stocks.
Get Annovis Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Annovis Bio Competitors List
Related Companies and Tools
